share_log

CRISPR Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-ARK Investment Management LLC(10.75%)

CRISPR Therapeutics | SC 13G/A:超過5%持股股東披露文件(修正)-ARK Investment Management LLC(10.75%)

SEC announcement ·  01/29 16:07
Moomoo AI 已提取核心訊息
ARK Investment Management LLC, an investment adviser based in Delaware, United States, has filed an amended Schedule 13G with the United States Securities and Exchange Commission on January 29, 2024, indicating a change in their holdings of CRISPR Therapeutics AG common stock. As of December 31, 2023, ARK Investment Management LLC reported beneficial ownership of 8,536,104 shares of CRISPR Therapeutics, representing 10.75% of the class. The filing shows that ARK has sole voting power over 8,057,147 shares and shared voting power over 244,377 shares. Additionally, ARK has sole dispositive power over the entire 8,536,104 shares it holds. The filing was made under Rule 13d-1(b) of the Securities Exchange Act of 1934, which is typically used by passive investors to report their holdings.
ARK Investment Management LLC, an investment adviser based in Delaware, United States, has filed an amended Schedule 13G with the United States Securities and Exchange Commission on January 29, 2024, indicating a change in their holdings of CRISPR Therapeutics AG common stock. As of December 31, 2023, ARK Investment Management LLC reported beneficial ownership of 8,536,104 shares of CRISPR Therapeutics, representing 10.75% of the class. The filing shows that ARK has sole voting power over 8,057,147 shares and shared voting power over 244,377 shares. Additionally, ARK has sole dispositive power over the entire 8,536,104 shares it holds. The filing was made under Rule 13d-1(b) of the Securities Exchange Act of 1934, which is typically used by passive investors to report their holdings.
總部位於美國特拉華州的投資顧問ARK Investment Management LLC已於2024年1月29日向美國證券交易委員會提交了經修訂的附表13G,表明其持有的CRISPR Therapeutics AG普通股發生了變化。截至2023年12月31日,方舟投資管理有限責任公司報告了CRISPR Therapeutics的8,536,104股股票的實益所有權,佔該類別的10.75%。文件顯示,ARK擁有超過8,057,147股股票的唯一投票權,對244,377股股票擁有共享投票權。此外,ARK對其持有的全部8,536,104股股票擁有唯一的處置權。該文件是根據1934年《證券交易法》第13d-1(b)條提交的,被動投資者通常使用該規則來報告其持有的股份。
總部位於美國特拉華州的投資顧問ARK Investment Management LLC已於2024年1月29日向美國證券交易委員會提交了經修訂的附表13G,表明其持有的CRISPR Therapeutics AG普通股發生了變化。截至2023年12月31日,方舟投資管理有限責任公司報告了CRISPR Therapeutics的8,536,104股股票的實益所有權,佔該類別的10.75%。文件顯示,ARK擁有超過8,057,147股股票的唯一投票權,對244,377股股票擁有共享投票權。此外,ARK對其持有的全部8,536,104股股票擁有唯一的處置權。該文件是根據1934年《證券交易法》第13d-1(b)條提交的,被動投資者通常使用該規則來報告其持有的股份。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息